What do systematic reviews say?

PRO 140 vs placebo

It is very uncertain whether PRO 140 changes antiviral response: 0.5 mg/kg compared with placebo (very low certainty).

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 3 [0.11, 83.36]
  1 study · 19 participants
  Very low

PRO 140 vs placebo

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 40 participants
  Very low

PRO 140 vs placebo

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 21 participants
  Very low

PRO 140 vs placebo

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 21 participants
  Very low

PRO 140 vs placebo

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 21 participants
  Very low

PRO 140 vs placebo

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

PRO 140 vs placebo

It is very uncertain whether PRO 140 changes antiviral response: 2 mg/kg compared with placebo (very low certainty).

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 27.44 [1.25, 601.57]
  1 study · 19 participants
  Very low

PRO 140 vs placebo

It is very uncertain whether PRO 140 changes antiviral response: 5 mg/kg compared with placebo (very low certainty).

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 439.09 [25.73, 7493.14]
  2 studies · 40 participants
  Very low

PRO 140 vs placebo

It is very uncertain whether PRO 140 changes antiviral response: 10 mg/kg compared with placebo (very low certainty).

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 145.67 [5.3, 4004.91]
  1 study · 21 participants
  Very low

PRO 140 vs placebo

It is very uncertain whether PRO 140 changes antiviral response: 162 mg weekly compared with placebo (very low certainty).

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 24.82 [1.17, 527.12]
  1 study · 21 participants
  Very low

PRO 140 vs placebo

It is very uncertain whether PRO 140 changes antiviral response: 324 mg weekly compared with placebo (very low certainty).

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 147 [5.35, 4037.48]
  1 study · 21 participants
  Very low

PRO 140 vs placebo

It is very uncertain whether PRO 140 changes antiviral response: 324 mg biweekly compared with placebo (very low certainty).

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 57 [2.59, 1253.22]
  1 study · 22 participants
  Very low

PRO 140 vs placebo

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 19 participants
  Very low

PRO 140 vs placebo

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 19 participants
  Very low

Intratympanic corticosteroids vs systemic corticosteroids

Intratympanic corticosteroids showed no clear difference in change in hearing threshold determined by PTA Range 0 dB to 140 dB… compared with systemic corticosteroids (low certainty).

• Intratympanic corticosteroids for sudden sensorineural hearing loss 2022 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 701 participants
  Low

Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone

Intratympanic plus systemic corticosteroids (combined therapy) showed no clear difference in change in hearing threshold determined by PTA Range 0 dB to 140 dB… compared with systemic corticosteroids alone (low certainty).

• Intratympanic corticosteroids for sudden sensorineural hearing loss 2022 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 435 participants
  Low

Intratympanic corticosteroids vs no treatment or versus placebo

Intratympanic corticosteroids showed no clear difference in change in hearing threshold determined by PTA Range 0 dB to 140 dB… compared with no treatment or versus placebo (low certainty).

• Intratympanic corticosteroids for sudden sensorineural hearing loss 2022 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 280 participants
  Low

Intervention not reported

It is very uncertain whether the intervention changes proportion of subjects with SBP < 140 mmHg and DBP < 90 mmHg (very low certainty).

• Alcohol intake reduction for controlling hypertension 2020 · Cochrane Headline outcomes only
  RR 1.21 [0.88, 1.65]
  1 study · 269 participants
  Very low

Intervention not reported

• Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta‐analysis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 140 participants
  Low